NCT00977548View on ClinicalTrials.gov

Erlotinib Study for Myelodysplastic Syndrome (MDS)

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

Erlotinib

Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00977548 - Erlotinib Study for Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter